Restorbio
CompanyUnited States
Restorbio develops 2 assets, the furthest approved (everolimus in advanced breast cancer). Mostly small molecule acting on mTOR signalling, autophagy and PIK3CA; based in the United States.
- Assets
- 2
- Furthest
- Approved
- Trials
- 1
- Signals
- 0
Pipeline
2Selective inhibitor of mTOR complex 1 (mTORC1)
ApprovedSmall moleculeAutophagymTOR signallingadvanced breast cancerAngiomyolipoma
Dual PI3K and mTOR inhibitor targeting age-related immunosenescence
Phase 2Small moleculemTOR signallingPIK3CArespiratory tract infection
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms3
- Trials1
- Similar companies6
Updated 7 Oct 2026 · 97 sources